Small molecule · developed by Veradermics
VDPHL01 is an extended release oral tablet studied in androgenetic alopecia, also called male pattern baldness, and in hair loss in women.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07146022 | Phase 3 | Androgenetic Alopecia (AGA) | Active not recruiting | MANE |
| NCT06724614 | Phase 2/3 | Androgenetic Alopecia | Active not recruiting | MANE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AGAAndrogenetic AlopeciaAndrogenetic Alopecia (AGA)Female Androgenetic AlopeciaHair LossMale Pattern Baldness
Updated Oct 18, 2026. Something wrong or missing? Report it on the MANE page.
See MANE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MANE catalysts and pipeline →